Navigation Links
CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
Date:10/18/2007

ATLANTA, Oct. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it will conduct its annual Cardiac Surgery Fellows Allograft Symposium on October 19, 2007, at the Company's corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provide a practical laboratory in which to demonstrate and practice the techniques for proper implant site preparation and allograft implantation.

The keynote speaker will be David C. McGiffin, M.D., Associate Director, Division of Cardiothoracic Surgery and Chief, Section of Cardiopulmonary Transplantation at the University of Alabama, Birmingham, Ala. The program will be attended by 27 surgery fellows from major U.S. surgical training institutions, and will be directed by Paul E. Stelzer, M.D., Senior Faculty, Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, N.Y.

Three additional distinguished cardiovascular surgeons complete the faculty of this program: John W. Fehrenbacher, M.D., Department of Cardiothoracic Surgery, CORVASC, Indianapolis, Ind; Francis Robicsek, M.D., Ph.D., Chairman, Department of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, N.C.; and Craig R. Saunders, M.D., Chairman, Cardiothoracic Surgery, Saint Barnabas Health Care System, Newark, N.J.

"The Cardiac Surgery Fellows Allograft Symposium creates a unique atmosphere in which to engage in thought provoking discussions about complex surgical procedures with leading cardiovascular surgeons in the field," said Dr. Stelzer. "The additional opportunity to practice allograft implantation techniques in a wet lab environment offers an invaluable educational opportunity for these cardiac fellows."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

Media Contacts:

D. Ashley Lee

Executive Vice President, Chief Operating Officer and

Chief Financial Officer

CryoLife, Inc.

Phone: 770-419-3355

Katie Brazel

Fleishman-Hillard

Phone: 404-739-0150


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Study explains unexpected conductivity of nanoscale silicon
2. Engineers chart semiconductors on the scale of atoms
3. NameProtect releases annual list of top trademarkers
4. Doyle says new contracts saving state more than $16 million annually
5. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
6. Annual Bioethics Forum to explore genetic testing
7. Annual Conference Honors Tech Grant Winners
8. Criticare gets OK to market portable cardiac monitor
9. Software to aid brain surgery is goal of Milwaukee startup
10. UW-Madison has 7 Sloan research fellows, top in nation
11. Symposium will include venture capital "coaching"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Franz Inc ., the leading supplier of Semantic Graph Database technology, ... by Bloor Research in its recent Graph Database Market Update report. ... Gruff, it was rated as the easiest product to use.” – Bloor Research , ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017 /PRNewswire/ ... launch single-cell sequencing during the American Association for Cancer ... Convention Center in Washington, D.C. , ... differential gene expression of thousands of cells at the ... Experts on-hand at AACR to discuss ...
(Date:3/28/2017)... HOLLISTON, Mass. , March 28, 2017 ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, today announced that Jim McGorry, ... 3D Printing and BioEngineering panel at the ... 2017 at 2:30 PM ET in Cambrige, Massachussetts. The ...
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
Breaking Biology Technology:
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
Breaking Biology News(10 mins):